Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This is an open-label, Phase I/II study of Intravitreally administered 0.3mg ranibizumab in subjects with persistent Diabetic Macular Edema (DME) after recent and frequent bevacizumab (at least 2 bevacizumab intravitreal injections within 2 months prior to enrollment and at least 6 bevacizumab injections within 9 months of enrollment).
Epistemonikos ID: 0ff0fd72a589d4ff82a9a5ba679fe0448059dd7d
First added on: May 11, 2024